drugset / Trial / NCT02608411

TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)

NCT02608411

Phase 2 Terminated 5 enrolled Veneto Institute of Oncology IRCCS
NaSingle-groupOpen-labelTreatment

Summary

This study aims to assess the role of MET inhibitors as maintenance treatment in adult patients with extensive stage small cell lung cancer.

Timeline

Start
2016-02-19
Primary completion
2017-02-21
Completion
2017-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivantinib Small molecule 360 mg Oral

Indications